Banff resident leaves $600,000 legacy to fight blindness – The Crag and Canyon

Doreen Powles legacy will impact people around the world as research discoveries transform lives by leading to treatments that restore sight. Thank you, Doreen, for your generosity, said Doug Earle, President and CEO, Fighting Blindness Canada.

Fighting Blindness Canada said they are grateful for the legacy gift of $600,000 by Banff resident, the late Doreen Marjorie Powles to fight blindness.

The announcement was made in Banff at the annual meeting of the Canadian Retina Society where Canadas retina specialists have gathered to share the latest in research and new treatments.

Fighting Blindness Canada is honoured to announce that Dr. Elizabeth M Simpson at the University of British Columbia is the recipient of the Doreen Powles Award to End Blindness for her project entitled Using gene therapy to Treat Congenital Blindness.

Doreen Powles spent her life in Banff where she lived with a blinding eye disease called congenital blindness. Her blindness was present at birth with reduced ability to detect light and colour, severe nearsightedness and involuntary movements of the eye.

Robert Smyth, executor of Doreen Powles estate said, Doreen was an only child. She left her entire estate to finance eye research, providing scholarships for aspiring researchers and helping people living with blindness. She would be excited by Fighting Blindness Canadas ground-breaking research to restore sight.

G.P. Powles, her father, was a partner in Hornibrook and Powles Insurance in Banff and a Rotarian.

Mr. Powles searched the world at great expense to find a cure for his daughters blindness without success.

Doreen Marjorie Powles graduated in 1952 from the University of British Columbia with a Bachelor of Arts.

Fighting Blindness Canada (FBC) is Canadas leading private funder of vision research. Over our 45-year history, we have invested over $40 million to support vision research and education across Canada with over 200 research grants that have led to over 600 new discoveries in areas such as stem cell research, neuroprotective therapies, technological developments, pharmaceuticals, and gene therapies.

View post:
Banff resident leaves $600,000 legacy to fight blindness - The Crag and Canyon

Exopharm publishes ‘positive and unique’ results for its exosome platform – Small Caps

Regenerative medicine company Exopharm (ASX: EX1) has received amiable results from a BioMAP testing program operated by Eurofins with respect to its exosome products.

Results showed that Exopharms exosome platform is safe in its mechanism of action and that has different and distinct activities compared to 4,500 other drugs.

Strong lab results raise the chances of Exopharms world-leading exosome products of becoming fully-fledged medicines although further testing is required.

The news is expected to have a positive impact across Exopharms business and will be of interest to potential customers, according to the companys chief executive officer Dr Ian Dixon.

The company said the results confirm this therapeutic approach is a distinct and potentially new class of medicine.

However, Exopharm did temper its positivity by admitting that BioMAP testing results may not translate to future testing in non-clinical or clinical trials and said that unforeseen product safety issues may arise at later stages of testing.

Eurofins BioMAP phenotypic profiling and screening service provides an objective, target agnostic and data-driven approach to understanding a medicines impact on human disease models and translational biomarkers.

Validated with clinically approved drugs and known test agents, the BioMAP platform is powered by human primary cell-based disease systems, a reference database of more than 4,500 compounds, data analytics, and expert interpretation to provide clients with actionable insights.

Headline BioMAP results indicated that Exopharms Plexaris product was safe in both relative and absolute terms and had notable biological activity in tissue remodelling, immunomodulatory and inflammatory-related activities.

Exosomes are natural particles produced by cells, delivering whats known as therapeutic cargoes to other cells to reduce inflammation and promote regeneration.

According to researchers, exosomes are plentiful in young individuals but decline with age.

Recent research has indicated that exosomes can be used as a way of extending the number of healthy functional years extending life quality and span.

Moreover, exosomes secreted by stem cells could be used as a substitute for stem-cell therapy with equal or greater benefit while avoiding various problems associated with stem-cell therapy.

Exopharm said exosome could even be used to deliver targeted novel drugs and serve a diagnostic function within various applications.

In parallel to Plexaris, Exopharms Cevaris product was compared with 4,500 experimental and sold medicines across a panel of 12 human primary cell-based systems.

Cevaris was found to be safe and had notable biological activity in the same areas as Plexaris.

Importantly, neither was shown to be cytotoxic, and neither caused antiproliferative effects at the concentrations tested.

Another key finding was that comparing the screening profiles of both Plexaris and Cevaris against the database of 4,500 medicines did not produce a significant match, thereby suggesting that both Plexaris and Cevaris have different and distinct activities in comparison to existing drugs.

This is a valuable finding, pointing to exosomes as a unique and potentially new class of medicine, with potential application unmet by existing medicines, the company said.

These are very positive results from a detailed external test of two of our experimental exosome products, said Dr Ian Dixon.

The testing showed that both Plexaris and Cevaris had different and distinct activities to comparison drugs. This confirms our belief that exosomes are a distinct and potentially new class of medicine, different from existing medicines.

The results of the BioMAP testing will help Exopharm plan its next studies with additional insights and confidence. After that, further human clinical trials are the next step, said Dr Dixon.

Moving forward, Exopharm said the results indicate several potential mechanisms of action and biological pathways for Plexaris and Cevaris, that will be verified in planned upcoming non-clinical studies.

Read the rest here:
Exopharm publishes 'positive and unique' results for its exosome platform - Small Caps

Medical Aesthetics Market Is Expected To Grow At CAGR Of 11.5% From 2019 To Reach $22.2 Billion By 2 (1) – PharmiWeb.com

Meticulous Research leading global market research company published a research report titled Medical Aesthetics Market by Product (Facial Aesthetics, Cosmetic Implants, Skin Aesthetic Devices, Thread Lift Products, Body Contouring Devices, Hair Removal Devices), End User (Hospitals, Medical Spas, Home Care Settings)Global Forecast to 2025.

According to this latest publication from Meticulous Research, the global medical aesthetics market is expected to grow at a CAGR of 11.5% from 2019 to reach $22.2 billion by 2025. The growth of this market will be driven by factors such as increasing adoption of minimally invasive and noninvasive aesthetic procedures, increasing public awareness about cosmetic procedures, and rising adoption of medical aesthetic procedures among geriatric population to improve their appearance. However, risk and complications associated with medical aesthetic procedures may hamper the growth of the market to a certain extent.

Get Inside Scoop Of The Report, Download For Free Sample PDF @https://www.meticulousresearch.com/download-sample-report/cp_id=5028(Note: Sample PDF Download with TOC, Charts, and Graphs)

Key questions answered in the report-Which are the high growth market segments in terms of products, technology, disease type, end user, and region/countries?What was the historical market for medical aesthetics market across the globe?What are the market forecasts and estimates for the period 2018-2025?What are the major drivers, opportunities, and challenges in the global medical aesthetics market?Who are the major players in the global medical aesthetics market?How is the competitive landscape and who are the market leaders in the global medical aesthetics market?What are the recent developments in the global medical aestheticsmarket?What are the different strategies adopted by the major players in the global medical aesthetics market?What are the geographical trends and high growth regions/ countries?Who are the local emerging players in the global medical aesthetics market and how do they compete with the global players?

Have Any Query? Ask Our Experts Here:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5028

The global medical aesthetics market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2025- by product (facial aesthetics, cosmetic implants, skin aesthetic devices, physician-dispensed cosmeceuticals and skin lighteners, thread lift products, body contouring devices, hair removal devices, tattoo removal devices, and nail treatment laser devices), and end user (hospitals, clinics, and medical spas, beauty centers, and home care settings). The study also evaluates industry competitors and analyzes the market at a regional and country level.

On the basis of product type, facial aesthetics market segment is estimated to command the largest share of the global medical aesthetics market in 2019; whereas, cosmetic implants segment is expected to grow at the highest CAGR during the forecast period due to increasing growth of minimally invasive reconstruction surgeries, technological advancements such as injectable fillers and gummy bear breast implants, rising number of congenital face disorders, and increasing awareness about aesthetic appearance. A comprehensive range of cosmetic plastic surgery techniques and implants have been developed over the years for improving the appearance or restoring function to the human body. The implants used in cosmetic procedures are to enhance the aesthetic looks of an individual and rectify the deformities caused due to accidents, trauma, and congenital disorders.

On the basis of end user, hospitals, clinics, and medical spas segment is estimated to hold the largest share of the global medical aesthetics market in 2019. Hospitals, clinics, and medical spas are typically well-equipped with technologically advanced instruments/devices and have skilled professionals to provide effective cosmetic treatment to its patients. This has led to their greater share in the global medical aesthetics market. Hospital and medical spas design their services to improve the aesthetic procedures for patient well-being. Medical aesthetic services involve highly advanced technology that needs the combination of healthcare and beauty services. In aesthetic treatment, advanced technologies are increasingly being used to provide medical procedures designed to offer significant cosmetic change for patients. The growth of the hospitals, clinics, and medical spas segment in the market is primarily driven by the growing number of patients undergoing cosmetic procedures to enhance self-esteem, increasing healthcare expenditure on cosmetic procedures, growing geriatric population, and greater uptake of technologically advanced medical aesthetics devices in the hospitals and clinics to provide effective treatments to the patients.

Browse key industry insights spread across 195 pages with 185 market data tables & 18 figures & charts from the market research report:https://www.meticulousresearch.com/product/medical-aesthetics-market-5028/

Geograhic Review:

This research report analyzes major geographies and provides comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, Italy, Spain, and U.K.), Asia-Pacific (China, India, South Korea, Japan, and Australia), Latin America, and Middle East & Africa. North America commanded the largest share of the global medical aesthetics market, followed by Europe and Asia Pacific. The largest share of North American region in the medical aesthetics market is primarily attributed to the growing healthcare sector, increasing awareness and adoption of aesthetic procedures among the population, growing healthcare expenditure, rising incidences of skin diseases, growing geriatric population, various technological advancements, and increase in the consciousness about physical appearances.

Asia Pacific region is expected to be the fastest growing geographic markets for medical aesthetics devices with countries, such as China, Japan, South Korea and India among others for being the largest contributors to the growth of the market. Additionally, rapid urbanization, increasing investments by healthcare providers towards infrastructure improvement, increasing awareness among the population, growing beauty consciousness, and availability of increasing range of advanced products and technologies is contributing to the growth of the medical aesthetics market in the Asia Pacific region.

Access Free Complete Free Sample PDF Copy Here:https://www.meticulousresearch.com/request-sample-report/cp_id=5028

Key players:

The major players operating in the globalmedical aesthetics marketare Allergan plc (Ireland), Alma Lasers (Israel), Anika Therapeutics, Inc. (US), Cutera, Inc. (US), Cynosure Inc. (US), El.En. S.P.A. (Italy), Fotona D.O.O (Solvenia& US), Galderma Laboratories, L.P. (US), Mentor Worldwide LLC (US), and Merz Aesthetics (Germany) among others.

Related Report:

Surgical Sutures Market by Product (Suture Thread (Synthetic, Nylon, Silk, Prolene, Steel), Automatic Suture Device), Application (CVD, General, Orthopedic, Gynec, Ophthalmic, Plastic, Cosmetics), End User (Hospitals, ASC, Clinic) Global Forecast to 2024

Flow Cytometry Market by Product (Cell Analyzers, Cell Sorter, Software, Reagents), Technology (Cell Based, Bead Based), Application (Drug Discovery, Stem Cell Research, Cancer, Organ Transplant, Commercial) and by End-user Global Forecast to 2027

Contact Us:Meticulous ResearchEmail-sales@meticulousresearch.comContact Sales- +1-646-781-8004Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

Original post:
Medical Aesthetics Market Is Expected To Grow At CAGR Of 11.5% From 2019 To Reach $22.2 Billion By 2 (1) - PharmiWeb.com

Lab-grown eggs and sperm a step closer – BioNews

10 February 2020

A study, published in Cell Reports, investigating when and how human stem cells develop into egg and sperm cells could one day help generate lab-grown gametes to treat infertility.

Human pluripotent stem cells can evolve into germ cells, which are the precursor cells for gamete development. By growing these human germ cells in vitro, the theory is that gametes engineered in a laboratory setting could someday be used, instead of natural eggs and sperm, in IVF treatment.

The research conducted within the Eli and Edythe Broad Centre of Regenerative Medicine and Stem Cell Research at University of California, Los Angeles (UCLA) provides great hope for those who are unable to produce gametes naturally,including thosewhose fertility has been affected by injury, illness or medical treatment.

'With donated eggs and sperm, the child is not genetically related to one or both parents. To treat patients who want a child who is genetically related, we need to understand how to make germ cells from stem cells, and then how to coax those germ cells into eggs or sperm'Dr Amander Clark, lead author of the study at UCLA, explained.

'Right now, if your body doesn't make germ cells, then there's no option for having a child that's biologically related to you. What we want to do is use stem cells to be able to generate germ cells outside the human body so that this kind of infertility can be overcome.'

In previous studies, scientists have been able to grow similarinduced pluripotent stem calls (iPS cells), and develop them into human skin cells and blood cells. The researchers, in collaboration with Massachusetts Institute of Technology, analysed the hundreds of thousands of genes active when both human embryonic stem cells and iPS cells transition to germ cells.

The data obtained allowed the researchers to firstly formulate when the germ cells are likely to form, which was between 24-48 hours after starting differentiation, and secondly which lineages of the differentiating stem cells give rise to the germ cells.

They also found that the activation and manifestation of germ cells was identical when developed from embryonic stem cells and iPS cells. This information was essential as they needed to ensure that the in vitro environment they had created was mimicking the molecular signals of the testis and ovaries to give hope for successful sperm and egg cell development.

Dr Clark stated: 'This tells us that the approach we're using to begin the process of making germ cells is on the right track. Now we're poised to take the next step of combining these cells with ovary or testis cells.'

Although current research is far from generating gametes, the end goal is that one day scientists are able to use a patient's skin cells to form stem cells, which can be programmed into egg or sperm cells to be used in fertility treatment.

See the original post:
Lab-grown eggs and sperm a step closer - BioNews

CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells – FierceBiotech

Personalized cell therapy CAR-T has made significant inroads in treating some forms of leukemia and lymphoma, but scientists hoping to translate the new technology to the second most common blood cancermultiple myelomahave faced some hurdles. A team at the University of Utahs Huntsman Cancer Institute (HCI) has early evidence that a new target called CD229 may help overcome those challenges.

CD229 is a molecule thats prevalent on the surface of both myeloma cells and stem cells, the latter of which produce treatment-resistant tumor cells. The HCI team engineered a human antibody against CD229 and created a CAR-T treatment that uses the antibody to target multiple myeloma cells. The CAR-T killed myeloma cells in mouse models of the disease, as well as stem cells from patients, the researchers reported in the journal Nature Communications.

Some of the biggest names in biopharma are racing to develop CAR-T treatments for multiple myeloma. They include Johnson & Johnson, which is targeting B-cell maturation antigen (BCMA) with its product JNJ-4528. At the American Society of Hematology conference in December, J&J released data from a small phase 1 study showing the treatment cleared tumors in 69% of patients with advanced multiple myeloma. A phase 2 study is slated to finish at the end of this year.

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

At the same conference, Bluebird Bio said that its multiple myeloma CAR-T, bb21217, which also targets BCMA, shrank tumors in 10 out of 12 patients given the lowest dose of the cells. Its the follow-up to bb2121, a BCMA-targeted CAR-T treatment that Bluebird is developing with Bristol-Myers Squibb unit Celgene.

RELATED: ASH: J&J's anti-BCMA CAR-T clears multiple myeloma in 69% of patients in phase 1

One nagging question about BCMA-based cell therapies is whether the responses they produce will be durable. Data released last May from an early trial of bb2121 didnt help alleviate that concern, as six of 15 patients who achieved a complete response ended up relapsing.

The HCI team set out to prove that targeting CD229 could improve durability by wiping out myeloma stem cells. As part of the study, they compared a BCMA-targeted CAR-T treatment with their CD229 CAR-Ts in samples taken from seven multiple myeloma patients. They found that their treatment produced a significant reduction in multiple-myeloma-propagating cells as compared to BCMA-targeted CAR-Ts.

We thought if we could target every last cancer cell in a patient's body, including the cancer stem cell, this could make the critical difference and yield more durable, deeper responses to treatment, said Djordje Atanackovic, M.D., associate professor at the University of Utah, in a statement.

The next step for the HCI researchers is to complete further studies to determine whether the CD229-targeted CAR-T cells will be safe to use in people. From there, they hope to move the therapy into clinical trials.

Read more:
CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells - FierceBiotech

Cynata Therapeutics aims for commercial production of cutting-edge STEM cell products – Proactive Investors Australia

The Australian clinical-stage stem cell and regenerative medicine company is focused on the development of stem cell platform technology for commercial production with the help of pharmaceutical partner Fuji Film.

() is ready to move up to scalable production of its graft-versus-host disease (GvHD) drug after a clinical trial proved the safety and efficacy of the drug.

Cynata managing director and chief executive officer Dr Ross Macdonald told Proactive that showing the product had a desirable clinical effect in people was an excellent result for the company.

He said: We achieved all of the study endpoints, demonstrating primarily the safety of the product but also efficacy, and therein lies one of the secrets to success in biotech land, which is demonstrating that the product or technology works in humans.

The trial results included a 54% complete response rate, an 87% overall response rate and a greater than 87% survival rate of patients using the GvHD drug.

Not only is the technology safe and effective, it also bypasses complex and invasive surgeries for patients and hospitals, and lowers costs incurred by healthcare systems.

Cynatas Cymerus technology overcomes the challenges of other production methods to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Macdonald said this putCynata ahead of the pack in terms of commercial product development.

He said: For a small Aussie company with a hundred million or so market cap to be the leader in the world in this area - and theres no dispute about that as for this particular type of cell therapy we are well and truly the leader as first company to complete a clinical study its really a very exciting place to be.

The technology provides a consistent manufacturing process - and that consistency and reproducibility is a vital element of successful drug product development.

The company now has the full support and resources to achieve commercial production after signing on the dotted line with new partner, pharmaceutical giant, Fuji Film.

Macdonald said: Australia is a great place for medical research and development, but it has some limitations when it comes to access to the amount of capital thats required to fully develop a drug product.

Instead of trying to squeeze blood out of a stone, our strategy was to access the necessary resources through partnership.

Fuji Film isvery active in pharmaceuticals and in the manufacture of drug products and thats what drew us together.

Its also consistent with our strategy of partnering our technology with global players who have the capacity and the access to resources that are necessary to ultimately bring our drug product to market.

Cynata's Cymerus platform has potential applications across a wide range of diseases

Fuji Film now has global rights to Cynatas first product, GvHD, and hasalready paid a US$3 million licence fee, bought US$3 million worth of stock at a 35% premium, and will pay further US$40 million in milestones plus a double-digit royalty on product sales.

Macdonald said: This year they expect to start a phase two clinical trial.

In Fuji Films hands, GvHD is expected to get to market sometime late in 2022 or early 2023.

Cynata has three fully-funded clinical trials upcoming, one is the phase two GvHD trial with Fuji Film, one is in Osteoarthritis (OA) which is funded by the Australian Government and one is in critical limb ischemia (CLI).

Macdonald said: You can cure cancer in rats but if you cant cure cancer in humans you dont have a product.

It comes down to being able to generate really good, solid data from clinical trials that prove that your product is safe and effective thats the sort of data we are seeking to generate to really drive shareholder value and become catalysts for shareholders to enjoy a significant uplift.

Data is what drives value in biotech land.

The company states that GvHD has an estimated market opportunity of US$0.3 billion, CLI has an estimated market opportunity of US$1.4 billion and OA has an estimated market opportunity of US$11.6 billion.

Consequentially, interest from major pharmaceutical companies in these areas of cell therapeutics is increasing.

Macdonald said this was one of the reasons Cynata recently knocked back a takeover bid which it believed undervalued the company.

He said: Last year the company received takeover bids, one of which was disclosed to the market at $2 per share.

Ultimately, we decided not to go ahead with that, but its a nice position to be in when a global, major pharmaceutical company decides that the technology looks exciting enough that theyre prepared to pay a couple of hundred million dollars for it.

That was also important validation of our technology and our strategy.

Continue reading here:
Cynata Therapeutics aims for commercial production of cutting-edge STEM cell products - Proactive Investors Australia

Trending 2020 : Stem Cell Therapy Market Report Examines Analysis by Latest Trends, Growth Factors, Key Players and Forecast to 2026 – Instant Tech…

The research report Stem Cell Therapy Market Analysis 2020 provides an estimate of the market size from 2020 to 2026 in terms of value and volume. It also includes a full assessment of key market segments and Stem Cell Therapy Market shares with the latest Trends and technologies used in the energy industry, as well as an instructive overview of the vendor landscape and geographic expansion of the market. The research study examines the Stem Cell Therapy Market based on a number of criteria such as Product Type, Application and geographic extent. The market shares of these segments are formulated in such a way that they offer readers of the Stem Cell Therapy Market an opportunistic Roadmap.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Looking for custom Stem Cell Therapy Market knowledge to strengthen your business for the future, Request a Sample Report @https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=ITN&utm_medium=002

[Note: our free sample report provides a brief introduction to the table of contents, table of contents, list of tables and figures, competitive landscape and geographic segmentation, as well as innovations and future developments based on research methods.]

The Stem Cell Therapy Market report is an important research document for target groups such as manufacturers, raw material suppliers and buyers, industry experts and other companies. First, the report talks about the Stem Cell Therapy Market Overview, which helps in the Definition, classification and statistical Details of the market gives information about the current market status and the future forecast. In the next part in a row, the report describes the drivers and constraints that influence the market, as well as various market trends that shape the supply and distribution chains of the market. The Stem Cell Therapy Market report also looks at market dynamics covering emerging markets and growing markets, although new opportunities and business challenges for emerging market participants along with key industry news and business policy by region.

The top manufacturer with company profile, sales volume, and product specifications, revenue (Million USD) and market share

Global Stem Cell Therapy Market Competitive Insights

The competitive analysis serves as a bridge between manufacturers and other participants that are available on the Stem Cell Therapy Market. The report includes a comparative study of Top market players with company profiles of competitive companies, Stem Cell Therapy Market product innovations and cost structure, production sites and processes, sales details of past years and technologies used by them. The Stem Cell Therapy Market report also explains the main strategies of competitors, their SWOT analysis and how the competition will react to changes in marketing techniques. In this report, the best market research techniques were used to provide the latest knowledge about Stem Cell Therapy Market to competitors in the market.

Global Stem Cell Therapy Market Segmentation information

The report provides important insights into the various market segments presented to simplify the assessment of the global Stem Cell Therapy Market. These market segments are based on several relevant factors, including Stem Cell Therapy Market product type or services, end users or applications and regions. The report also includes a detailed analysis of the regional potential of the Stem Cell Therapy Market, which includes the difference between production values and demand volumes, as well as the presence of market participants and the growth of each Region over the given forecast period

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=ITN&utm_medium=002

Stem Cell Therapy Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Stem Cell Therapy markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Stem Cell Therapy industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Stem Cell Therapy industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Stem Cell Therapy industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Stem Cell Therapy industry.

Market Dynamics: The report offers deep insights into the dynamics of the Stem Cell Therapy industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Stem Cell Therapy industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Stem Cell Therapy industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Stem Cell Therapy industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Stem Cell Therapy industry.

What will you find out from the global Stem Cell Therapy Market Report?

The report contains statistical analyses of the current and future Status of the global Stem Cell Therapy Market with a forecast to 2026.The report contains detailed information on manufacturers, Stem Cell Therapy Market raw material suppliers and buyers with their trade outlook for 2020-2026.The report informs you about the most important drivers, technologies and Trends that will shape the global Stem Cell Therapy Market in the near future.The report added an exclusive market segmentation, broken down by Product Type, Stem Cell Therapy Market end user and Region.The strategic perspectives on Stem Cell Therapy Market Dynamics, current production process and applications.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=ITN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

More:
Trending 2020 : Stem Cell Therapy Market Report Examines Analysis by Latest Trends, Growth Factors, Key Players and Forecast to 2026 - Instant Tech...

MS News that Caught My Eye Last Week: Methionine, MSCT, Spinal… – Multiple Sclerosis News Today

Methionine is an amino acid found in meat, eggs, and dairy. Its absorbed by T-cells that are part of our immune system. Those cells are also believed to be the immune cells that attack our myelin, creating the nerve damage that results in multiple sclerosis.

In this study, mice eating less methionine had a reduced number of a certain type of T-cell, which led to a delay in disease onset and progression. The researchers believe reducing methionine intake can actually dampen the immune cells that cause disease, leading to better outcomes.

Changing a persons diet to reduce the amount of methionine (amino acid found in food) could delay the development and progression of inflammatory and autoimmune disorders, including multiple sclerosis (MS).

That finding was described in the study Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming, published recently in the journal Cell Metabolism.

Click here to read the full story.

***

Unlike hematopoietic stem cell transplants, in which stem cells are removed from a patients bone marrow and later infused back into the bloodstream, mesenchymal stem cell transplants (MSCT) collect those stem cells from the patients spinal column and return them there. This study concludes that MSCT is safe and that cells delivered into the spinal cord produced a significantly slower disease progression rate than did cells delivered into the bloodstream.

Transplanting patients ownmesenchymal stem cellsis a safe therapeutic approach and can delay disease progression in people with MS, a meta-analysis review shows.

The study also showed that cells transplanted to the spinal cord (intrathecal injection) were associated with significantly slower disease progression rates, compared to cells delivered into the bloodstream.

Click here to read the full story.

***

Why do neurologists often use spinal taps when determining whether someone has MS? This study provides one of the reasons.

People with MS have a more diverse set of immune cells in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, but no such diversity is seen in their blood, a study reports. Instead, MS causes changes in the activation of immune cells in the blood.

The distinct set of immune cells in MS patients CSF shows enrichment of pro-inflammatory cells that promote disease severity in MS mouse models.

Click here to read the full story.

***

Heres encouraging news about a possible treatment that can lower the number of brain lesions in someone with MS. Keep in mind this is only a Phase 2 trial. A Phase 3 trial isnt expected until later this year. However, a news release from research sponsor Sanofisays, This molecule may be the first B-cell-targeted MS therapy that not only inhibits the peripheral immune system, but also crosses the blood-brain barrier to suppress immune cells that have migrated into the brain.

The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint a significant reduction in the number of new lesions visible on a brain imaging scan in a Phase 2 trial in people with MS, study results show.

SAR442168, formerly known as PRN2246, is an oral, small molecule being co-developed by Principia Biopharmaand Sanofi Genzyme. It works by inhibiting Brutons tyrosine kinase (BTK), a protein important for the proliferation of immune cells, particularly B-cells. By blocking BTK, it is expected that SAR442168 can reduce inflammation that damages the nervous system in people with MS.

Click here to read the full story.

Did you know that some of my columns from The MS Wire are now available as audio briefings? You can listen to them here.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

See original here:
MS News that Caught My Eye Last Week: Methionine, MSCT, Spinal... - Multiple Sclerosis News Today

Stem Cell Therapy Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 – TechNews.mobi

An exclusive Stem cell therapy Market research report has been fabricated through the in depth analysis of the market dynamics across five regions including North America, Europe, South America, Asia-Pacific, Middle East and Africa. The segmentation of the market by components, end users, and region was done based on the thorough market analysis and validation through extensive primary inputs from industry experts (key opinion leaders of companies, and stakeholders) and secondary research (global/regional associations, trade journals, technical white papers, companys website, annual report SEC filing, and paid databases). Further, the market has been estimated by utilizing various research methodologies and internal statistical model.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100000991/

The key players influencing the market are:

This report contains:

Stem cell therapy Market report also provide a in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner Stem cell therapy Market revenue by understanding the strategic growth approaches.

Stem cell therapy Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2020 2027, considering 2020 as the base year and 2020 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Tags: Stem cell therapy MarketStem cell therapy Market 2019Stem cell therapy Market AnalysisStem cell therapy Market By ApplicationStem cell therapy Market By TypeStem cell therapy Market DevelopmentStem cell therapy Market ForecastStem cell therapy Market Forecast To 2027Stem cell therapy Market Future InnovationStem cell therapy Market Future TrendsStem cell therapy Market In AsiaStem cell therapy Market In AustraliaStem cell therapy Market In EuropeStem cell therapy Market In FranceStem cell therapy Market In GermanyStem cell therapy Market In Key CountriesStem cell therapy Market In United KingdomStem cell therapy Market Is BoomingStem cell therapy Market Latest ReportStem cell therapy Market SizeStem cell therapy Market Size In United StatesStem cell therapy Market Swot Analysis

View original post here:
Stem Cell Therapy Market Global Production, Growth, Share, Demand and Applications Forecast to 2027 - TechNews.mobi

Glantz: Taking the ‘bad man’ test | Local News – The Times Herald

The official definition of the witching hour is when witches -- or magicians, ghouls, Republican senators and other demons -- are said be at their most powerful.

Thats the myth, the folklore.

The reality is that the witching hour is when we wake up in the middle of the night and our minds are clear enough to be haunted by our own bitter realities.

Unanswerable questions, many about futures we cant control, ravage the brain.

I was hit with one so immediate this past week that not even my home remedy sneaking downstairs for some old Sopranos episodes could make it right.

The question was this: Am I a bad person?

Here are three examples, hot off the presses, that had me wondering:

Andy Reid Much of Eagles Nation has forgiven and forgotten the specifics of the Reid Era here. They instead focus on the general success between 1999 and 2012.

But not me. I remember high hopes repeatedly dashed, and the seasons that ended in despair.

I invested too much in time, emotion and money (season ticket holder) -- to be stranded at the altar again and again and again.

Maybe some forget the feeling of having their hearts eaten out that were then met with the subsequent kick in our collective gut when Reid would act smug and indifferent during postgame press conferences.

Even when mishaps (dropped passes, missed tackles) werent directly his fault, Reids standard line was it begins with me.

Fine, Andy, you wanted the blame, you got it. I would have told you so if they let me to drive you to the airport when you left town.

Why, then, would I or anyone else who bleeds green root for Reid to have success elsewhere?

There was no worse scenario than his new team, the Kansas City Chiefs, winning a Super Bowl when he didnt do it in Philly after all those years of knocking on the door without finding a way to kick it in.

When we finally got it done two years ago, some of the edge was taken off. Still, when the Chiefs reached the big dance this year, I became a temporary fan of the opposing San Francisco 49ers.

Truth be told, I am more than a little bit angry with the end result (particularly the touchdown that wasnt a touchdown) and irked by all the glad tidings for Reid around the Delaware Valley.

Bad person?

Self-vote: Yeah, sigh, I am. Its not like he tried to lose big games here (it just seemed like it).

Iowa Caucuses I have been a detractor of the overall primary system for a long time, and my criticism begins with the disproportionate role little Iowa plays in the process.

I wrote all about it in my Sunday column a month or two ago, but I never could have imagined the Monday meltdown that will leave the final tally with an asterisk.

The root cause of the chaos was the already silly caucus process being further complicated with some second-round scenario that was clearly over the heads of those Iowa straw-chewers to comprehend.

While the good news is that this is probably the last we will see of the Iowa Caucuses, and maybe even Iowa getting to bat leadoff and set the pace as it has been doing, despite clearly not being a gauge of Americas diversity (its well over 90 percent lilywhite, for example) the embarrassment for the Democratic party could prove to be colossal.

Bad person?

Self-vote: Nope, not at all. A little bit of vindication is good for the soul.

Rush Limbaugh The right-wing AM Talk Radio host revealed that he is terminally ill.

If you are waiting for tears, keeping waiting.

I understand the man may have had a job to do, sort of in the Howard Stern shock jock sense, and that he may or may not have even meant half the hateful things he was saying.

But listeners many with pea brains accepted his postulating as fact.

And he knew it.

And he kept on spewing his garbage -- ironically losing his own hearing, so he couldnt even hear himself anymore.

If we are truly mired in a modern day Civil War, one in which lives (i.e. Heather Heyer) have been lost, Limbaugh is a general in the militia that fired the first shots (albeit away from the fray while on his bully pulpit).

It could be said that there would have been no coming of your president (not mine), without Limbaugh among others laying the groundwork.

No wonder Limbaugh got the Presidential Medal of Freedom the other night.

Hard to believe, though, considering this is the same person who called Iraq War veterans subsequently opposed to the war phony soldiers.

Then again, this prize was given to him by the phoniest of soldiers, one who got out of Vietnam with phantom bone spurs.

Like your president (not mine), Limbaugh built his empire on lies and half-truths.

Consider that Polifact rated Limbaughs on-air statements as either mostly false or pants on fire at a rapid-fire rate of 84 percent, with only a mere 5 percent registering as true.

While a lot of his false statements are about climate change, we are also talking about someone who continually degraded President Barack Obama with racially charged innuendoes calling him (and Oprah Winfrey) uppity, etc. and who compared NFL games to showdowns between black gangs.

He also said actor Michael J. Fox was exaggerating his Parkinsons disease in an ad for stem cell research.

I wonder if hed like some of that stem cell research for himself now? Maybe he is just exaggerating his symptoms.

Take the high road? Not this so-called snowflake. Its all low road here in Gordonville.

Bad person?

Self-vote: Abstain.

Originally posted here:
Glantz: Taking the 'bad man' test | Local News - The Times Herald